Regulatory Bayer gets swift review for Kerendia in type 1 diabetes PharmaphorumFDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.Metabolic & GLP-1Read full story pharminent May 21, 2026 (Last updated: May 21, 2026) Pharmaphorum FDA starts a priority review of Bayer’s Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ATS 2026: PABPC4 gene identified as a key driver of emphysema in COPDNext: FUJIFILM opens new iPSC facility in Madison, US Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
